JP2017501711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501711A5 JP2017501711A5 JP2016541346A JP2016541346A JP2017501711A5 JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5 JP 2016541346 A JP2016541346 A JP 2016541346A JP 2016541346 A JP2016541346 A JP 2016541346A JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 58
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 238000000034 method Methods 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 5
- 102000003816 Interleukin-13 Human genes 0.000 claims 4
- 108090000176 Interleukin-13 Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000012350 deep sequencing Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020092097A JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919552P | 2013-12-20 | 2013-12-20 | |
| US61/919,552 | 2013-12-20 | ||
| US201461946547P | 2014-02-28 | 2014-02-28 | |
| US61/946,547 | 2014-02-28 | ||
| PCT/US2014/071193 WO2015095539A1 (en) | 2013-12-20 | 2014-12-18 | Dual specific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092097A Division JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017501711A JP2017501711A (ja) | 2017-01-19 |
| JP2017501711A5 true JP2017501711A5 (Direct) | 2018-02-08 |
| JPWO2015095539A5 JPWO2015095539A5 (Direct) | 2022-03-09 |
| JP7325166B2 JP7325166B2 (ja) | 2023-08-14 |
Family
ID=52293284
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541346A Active JP7325166B2 (ja) | 2013-12-20 | 2014-12-18 | 二重特異性抗体 |
| JP2020092097A Active JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
| JP2023134016A Withdrawn JP2023179409A (ja) | 2013-12-20 | 2023-08-21 | 二重特異性抗体 |
| JP2025133768A Pending JP2025179073A (ja) | 2013-12-20 | 2025-08-08 | 二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092097A Active JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
| JP2023134016A Withdrawn JP2023179409A (ja) | 2013-12-20 | 2023-08-21 | 二重特異性抗体 |
| JP2025133768A Pending JP2025179073A (ja) | 2013-12-20 | 2025-08-08 | 二重特異性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10683348B2 (Direct) |
| EP (1) | EP3083682B1 (Direct) |
| JP (4) | JP7325166B2 (Direct) |
| KR (3) | KR102597804B1 (Direct) |
| CN (2) | CN105849124B (Direct) |
| BR (1) | BR112016011027A2 (Direct) |
| CA (2) | CA3204788C (Direct) |
| MX (2) | MX380937B (Direct) |
| RU (1) | RU2732032C2 (Direct) |
| WO (1) | WO2015095539A1 (Direct) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067896T2 (hu) | 2016-04-27 | 2024-11-28 | Abbvie Mfg Management Unlimited Company | Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN110382696B (zh) * | 2017-03-07 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 发现替代性抗原特异性抗体变体的方法 |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| PL3606954T3 (pl) | 2017-04-05 | 2022-10-17 | F. Hoffmann-La Roche Ag | Przeciwciała anty-LAG3 |
| TWI801425B (zh) | 2017-09-29 | 2023-05-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Il-5 抗體、其抗原結合片段及醫藥用途 |
| WO2019122052A2 (en) | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/wt1 |
| JP2021511793A (ja) | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体 |
| CN111630063A (zh) | 2018-01-31 | 2020-09-04 | 豪夫迈·罗氏有限公司 | 稳定化的免疫球蛋白结构域 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| JP2021512914A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法 |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| MX2020010028A (es) | 2018-03-29 | 2020-10-14 | Genentech Inc | Actividad lactogenica modulada en celulas de mamifero. |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| BR112021011939A2 (pt) | 2018-12-21 | 2021-09-14 | F. Hoffmann-La Roche Ag | Anticorpo que se liga a cd3, anticorpos que se ligam a cd3 e tyrp-1, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3, composição farmacêutica e usos do anticorpo |
| US20220073630A1 (en) | 2018-12-28 | 2022-03-10 | Hoffmann-La Roche, Inc. | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
| US12465640B2 (en) | 2019-02-25 | 2025-11-11 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents |
| MX2021011530A (es) | 2019-03-29 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. |
| US12392777B2 (en) | 2019-04-02 | 2025-08-19 | National Research Council Of Canada | Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors |
| AU2020268896B2 (en) | 2019-05-03 | 2024-11-28 | F. Hoffmann-La Roche Ag | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
| AU2020306672B2 (en) | 2019-06-26 | 2023-08-24 | F. Hoffmann-La Roche Ag | Mammalian cell lines with SIRT-1 gene knockout |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CN114174338A (zh) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
| BR112022001460A2 (pt) | 2019-07-31 | 2022-03-22 | Hoffmann La Roche | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção |
| CN114423791B (zh) | 2019-09-18 | 2026-01-09 | 豪夫迈·罗氏有限公司 | 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法 |
| BR112022008172A2 (pt) | 2019-11-15 | 2022-07-12 | Hoffmann La Roche | Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica |
| US11987632B2 (en) | 2019-12-18 | 2024-05-21 | Hoffmann-La Roche Inc. | Antibodies binding to HLA-A2/MAGE-A4 |
| US11739142B2 (en) | 2019-12-18 | 2023-08-29 | Hoffmann-La Roche Inc. | Bispecific anti-CCL2 antibodies |
| PH12022551496A1 (en) | 2019-12-23 | 2023-12-11 | Genentech Inc | Apolipoprotein l1-specific antibodies and methods of use |
| WO2021144422A1 (en) | 2020-01-15 | 2021-07-22 | F. Hoffmann-La Roche Ag | Methods to decrease impurities from recombinant protein manufacturing processes |
| US12098365B2 (en) | 2020-03-26 | 2024-09-24 | Genentech, Inc. | Modified mammalian cells |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
| CN115605185A (zh) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途 |
| CN115697489A (zh) | 2020-06-08 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 抗hbv抗体及其使用方法 |
| CR20220628A (es) | 2020-06-19 | 2023-01-24 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
| BR112022025856A2 (pt) | 2020-06-19 | 2023-01-10 | Hoffmann La Roche | Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção |
| CR20220639A (es) | 2020-06-19 | 2023-02-17 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y folr1 |
| WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
| IL299161A (en) | 2020-06-24 | 2023-02-01 | Genentech Inc | Cell lines resistant to apoptosis |
| WO2022008468A1 (en) | 2020-07-07 | 2022-01-13 | F. Hoffmann-La Roche Ag | Alternative surfactants as stabilizers for therapeutic protein formulations |
| BR112023000839A2 (pt) | 2020-07-17 | 2023-02-07 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo |
| TW202227625A (zh) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除 |
| AU2021347580A1 (en) | 2020-09-24 | 2023-04-06 | F. Hoffmann-La Roche Ag | Mammalian cell lines with gene knockout |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| EP4244248A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Fab high mannose glycoforms |
| WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
| WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
| EP4281474A4 (en) * | 2021-01-21 | 2025-03-05 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
| WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CN117062839A (zh) | 2021-03-12 | 2023-11-14 | 基因泰克公司 | 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法 |
| EP4320444A1 (en) | 2021-04-09 | 2024-02-14 | F. Hoffmann-La Roche AG | Process for selecting cell clones expressing a heterologous polypeptide |
| IL307501A (en) | 2021-04-19 | 2023-12-01 | Hoffmann La Roche | Modified mammalian cells |
| EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
| KR20240021859A (ko) | 2021-06-18 | 2024-02-19 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ccl2 항체 |
| KR20240032930A (ko) | 2021-07-13 | 2024-03-12 | 제넨테크, 인크. | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 |
| WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
| EP4380980A1 (en) | 2021-08-03 | 2024-06-12 | F. Hoffmann-La Roche AG | Bispecific antibodies and methods of use |
| AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
| EP4416301B1 (en) | 2021-12-21 | 2025-06-11 | F. Hoffmann-La Roche AG | Method for the determination of hydrolytic activity |
| TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗ｎｏｔｃｈ２抗體及結合物及其使用方法 |
| JP7654346B2 (ja) * | 2022-03-03 | 2025-04-01 | ファイザー・インク | 多重特異性抗体およびその使用 |
| JP2025513335A (ja) | 2022-04-19 | 2025-04-24 | エフ． ホフマン－ラ ロシュ アーゲー | 改良された産生細胞 |
| CA3239182A1 (en) * | 2022-05-23 | 2023-11-30 | Zhipeng SU | Stable antibody preparation |
| JP2025522251A (ja) | 2022-05-30 | 2025-07-15 | ハナル バイオファーマ カンパニーリミテッド | 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片 |
| JP2025517572A (ja) | 2022-06-03 | 2025-06-05 | エフ． ホフマン－ラ ロシュ アーゲー | 改良された産生細胞 |
| IL317083A (en) | 2022-06-17 | 2025-01-01 | Apogee Biologics Inc | Antibodies that bind interleukin 13 and methods of use |
| JP2025523995A (ja) | 2022-07-22 | 2025-07-25 | ジェネンテック， インコーポレイテッド | 抗ｓｔｅａｐ１抗原結合分子およびその使用 |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| CN120019277A (zh) | 2022-10-12 | 2025-05-16 | 豪夫迈·罗氏有限公司 | 用于对细胞进行分类的方法 |
| EP4623086A1 (en) | 2022-11-23 | 2025-10-01 | F. Hoffmann-La Roche AG | Method for increasing recombinant protein expression |
| WO2024120517A1 (zh) | 2022-12-08 | 2024-06-13 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
| JP2025538819A (ja) | 2022-12-12 | 2025-11-28 | ジェネンテック， インコーポレイテッド | ポリペプチドシアル酸含有量の最適化 |
| CN120569410A (zh) | 2023-01-25 | 2025-08-29 | 豪夫迈·罗氏有限公司 | 与csf1r和cd3结合的抗体 |
| CN120826234A (zh) | 2023-03-06 | 2025-10-21 | 豪夫迈·罗氏有限公司 | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 |
| CN120858109A (zh) | 2023-03-10 | 2025-10-28 | 基因泰克公司 | 与蛋白酶的融合物及其用途 |
| KR20250167591A (ko) | 2023-03-31 | 2025-12-01 | 제넨테크, 인크. | 항-알파 v 베타 8 인테그린 항체 및 사용 방법 |
| CN121127493A (zh) | 2023-05-08 | 2025-12-12 | 豪夫迈·罗氏有限公司 | 靶向干扰素 α 融合蛋白及使用方法 |
| WO2024263761A1 (en) | 2023-06-22 | 2024-12-26 | Genentech, Inc. | Antibodies and uses thereof |
| WO2025021838A1 (en) | 2023-07-26 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025040567A1 (en) | 2023-08-18 | 2025-02-27 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
| JP2025036273A (ja) * | 2023-08-30 | 2025-03-14 | ファイザー・インク | 多重特異性抗体およびその使用 |
| AR133909A1 (es) | 2023-09-25 | 2025-11-12 | Hoffmann La Roche | ANTICUERPO QUE SE UNE A C3bBb |
| WO2025125386A1 (en) | 2023-12-14 | 2025-06-19 | F. Hoffmann-La Roche Ag | Antibodies that bind to folr1 and methods of use |
| WO2025132503A1 (en) | 2023-12-20 | 2025-06-26 | F. Hoffmann-La Roche Ag | Antibodies binding to ceacam5 |
| WO2025137086A1 (en) | 2023-12-20 | 2025-06-26 | Genentech, Inc. | Reducing alpha-gal |
| WO2025133042A2 (en) | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025181189A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2025215060A1 (en) | 2024-04-11 | 2025-10-16 | F. Hoffmann-La Roche Ag | Antibodies that specifically bind modified oligonucleotides |
| WO2026006162A2 (en) | 2024-06-24 | 2026-01-02 | Genentech, Inc. | B vitamin modulation |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| EP2386575A3 (en) * | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| JP4303105B2 (ja) * | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| UA94213C2 (ru) * | 2004-09-17 | 2011-04-26 | Домантис Лимитед | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |
| DK2059533T3 (da) * | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| TW200902725A (en) * | 2007-04-02 | 2009-01-16 | Genentech Inc | Biological markers predictive of rheumatoid arthritis response to B-cell antagonists |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JP5624114B2 (ja) * | 2009-03-20 | 2014-11-12 | ジェネンテック， インコーポレイテッド | 抗ｈｅｒ抗体 |
| JP5901517B2 (ja) * | 2009-05-28 | 2016-04-13 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗原結合性タンパク質 |
| RS64179B1 (sr) | 2011-05-27 | 2023-05-31 | Hoffmann La Roche | Dvostruko ciljanje |
| RU2015141529A (ru) * | 2013-04-05 | 2017-05-15 | Дженентек, Инк. | Антитела и биспецифические антитела к il-4 и их применение |
-
2014
- 2014-12-18 BR BR112016011027A patent/BR112016011027A2/pt not_active Application Discontinuation
- 2014-12-18 EP EP14824722.4A patent/EP3083682B1/en active Active
- 2014-12-18 KR KR1020167014866A patent/KR102597804B1/ko active Active
- 2014-12-18 JP JP2016541346A patent/JP7325166B2/ja active Active
- 2014-12-18 CA CA3204788A patent/CA3204788C/en active Active
- 2014-12-18 KR KR1020237037490A patent/KR20230155605A/ko not_active Ceased
- 2014-12-18 MX MX2016006529A patent/MX380937B/es unknown
- 2014-12-18 KR KR1020257033750A patent/KR20250154523A/ko active Pending
- 2014-12-18 CN CN201480067934.5A patent/CN105849124B/zh active Active
- 2014-12-18 CN CN202210315371.3A patent/CN114702594B/zh active Active
- 2014-12-18 CA CA2931113A patent/CA2931113C/en active Active
- 2014-12-18 RU RU2016129247A patent/RU2732032C2/ru active
- 2014-12-18 WO PCT/US2014/071193 patent/WO2015095539A1/en not_active Ceased
-
2016
- 2016-05-19 MX MX2021003549A patent/MX2021003549A/es unknown
- 2016-05-27 US US15/167,030 patent/US10683348B2/en active Active
-
2020
- 2020-04-28 US US16/860,891 patent/US12006360B2/en active Active
- 2020-05-27 JP JP2020092097A patent/JP7504664B2/ja active Active
-
2023
- 2023-08-21 JP JP2023134016A patent/JP2023179409A/ja not_active Withdrawn
-
2024
- 2024-04-29 US US18/648,653 patent/US20240279327A1/en not_active Abandoned
- 2024-12-13 US US18/980,433 patent/US20250109195A1/en not_active Abandoned
-
2025
- 2025-07-25 US US19/280,650 patent/US20250346661A1/en active Pending
- 2025-08-08 JP JP2025133768A patent/JP2025179073A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501711A5 (Direct) | ||
| RU2016129247A (ru) | Антитела с двойной специфичностью | |
| TWI508745B (zh) | ＴＮＦ－α結合蛋白 | |
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JPWO2015095539A5 (Direct) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| US20150344566A1 (en) | Dual specific binding proteins directed against il-13 and/or il-17 | |
| US20130171059A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2019536806A5 (Direct) | ||
| JP2017535257A5 (Direct) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2013507929A (ja) | Ｉｌ−１結合蛋白質 | |
| JP2018521638A5 (Direct) | ||
| TW201446800A (zh) | 針對ＴＮＦα之雙特異性結合蛋白 | |
| JP2017529838A5 (Direct) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2016524463A5 (Direct) | ||
| WO2014089209A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| JP2017533694A5 (Direct) | ||
| JP2010526028A5 (Direct) | ||
| TW201527322A (zh) | 骨關節炎及疼痛之治療 | |
| JP2020514277A5 (Direct) | ||
| JP2015503909A5 (Direct) | ||
| JP2017507131A5 (Direct) |